SIMILAR PATTERNS OF AMINO ACIDS FOR 3OCT_A_1N1A663_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 408 VAL A 416 LYS A 430 MET A 449 VAL A 458 GLY A 480 GLU A 488 LEU A 528	None	1.10A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 408 VAL A 416 LYS A 430 VAL A 458 TYR A 476 GLY A 480 GLU A 488 LEU A 528	None	0.93A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 416 ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528	None	0.86A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 416 LYS A 430 MET A 449 VAL A 458 THR A 474 GLY A 480 GLU A 488 LEU A 528	None	1.08A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 209 ALA A 220 LYS A 222 MET A 240 VAL A 249 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.59A	3octA-1k9aA: 32.3	3octA-1k9aA: 27.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	8	VAL A 588 ALA A 606 LYS A 608 MET A 629 VAL A 638 TYR A 656 GLY A 660 LEU A 731	None	1.04A	3octA-1lufA: 31.6	3octA-1lufA: 30.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 THR A 334 GLY A 340 GLU A 348 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	1.12A	3octA-1opkA: 32.5	3octA-1opkA: 28.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.71A	3octA-1rjbA: 29.8	3octA-1rjbA: 36.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 LYS A 644 MET A 665 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	1.00A	3octA-1rjbA: 29.8	3octA-1rjbA: 36.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 78 VAL A 86 ALA A 99 LYS A 101 VAL A 131 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.65A	3octA-1s9iA: 22.3	3octA-1s9iA: 24.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 MET A 410 VAL A 419 GLY A 441 LEU A 489	None	0.68A	3octA-1snxA: 14.9	3octA-1snxA: 56.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 595 VAL A 603 ALA A 621 LYS A 623 VAL A 654 THR A 670 TYR A 672 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-4.3A) STI A 3 (-3.2A) STI A 3 ( 4.0A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.70A	3octA-1t46A: 30.2	3octA-1t46A: 34.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 344 VAL A 352 ALA A 367 MET A 390 VAL A 399 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) None None STU A 100 (-3.5A) STU A 100 (-4.5A)	0.67A	3octA-1u59A: 29.9	3octA-1u59A: 37.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 15 VAL A 23 ALA A 36 LYS A 38 VAL A 68 TYR A 86 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-4.8A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A)	0.59A	3octA-1zltA: 22.4	3octA-1zltA: 24.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 ALA X 37 LYS X 39 MET X 58 VAL X 67 THR X 82 TYR X 84 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) None None STU X 902 (-4.1A) STU X 902 (-4.6A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.59A	3octA-2dq7X: 31.8	3octA-2dq7X: 38.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 VAL X 25 ALA X 37 LYS X 39 MET X 58 VAL X 67 THR X 82 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) None None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.62A	3octA-2dq7X: 31.8	3octA-2dq7X: 38.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 THR A 338 TYR A 340 GLY A 344 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None H8H A 534 (-3.1A) H8H A 534 (-4.3A) H8H A 534 (-3.3A) H8H A 534 (-4.5A)	0.52A	3octA-2h8hA: 29.9	3octA-2h8hA: 22.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 THR A 338 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.74A	3octA-2hckA: 29.8	3octA-2hckA: 26.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 251 VAL A 259 ALA A 271 LYS A 273 MET A 292 VAL A 301 THR A 316 GLY A 322 GLU A 332 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) None 1BM A 499 (-4.4A)	1.07A	3octA-2hk5A: 31.8	3octA-2hk5A: 40.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 248 VAL A 256 ALA A 269 LYS A 271 MET A 290 VAL A 299 THR A 315 GLY A 321 GLU A 329 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) None None GIN A 600 (-4.7A)	1.25A	3octA-2hz0A: 31.8	3octA-2hz0A: 45.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 ALA A 271 LYS A 273 MET A 292 THR A 316 TYR A 318 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.68A	3octA-2og8A: 31.0	3octA-2og8A: 42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 ALA A 271 LYS A 273 VAL A 301 THR A 316 TYR A 318 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.73A	3octA-2og8A: 31.0	3octA-2og8A: 42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 LYS A 273 VAL A 301 THR A 316 TYR A 318	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A)	0.69A	3octA-2og8A: 31.0	3octA-2og8A: 42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 ALA A 614 LYS A 616 MET A 637 TYR A 665 GLY A 669 LEU A 785	None	0.61A	3octA-2ogvA: 15.2	3octA-2ogvA: 33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 ALA A 614 MET A 637 VAL A 647 THR A 663 TYR A 665 GLY A 669 LEU A 785	None	0.70A	3octA-2ogvA: 15.2	3octA-2ogvA: 33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 VAL A 596 ALA A 614 LYS A 616 MET A 637 GLY A 669 LEU A 785	None	0.68A	3octA-2ogvA: 15.2	3octA-2ogvA: 33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 MET A 637 VAL A 647 THR A 663 GLY A 669 LEU A 785	None	0.71A	3octA-2ogvA: 15.2	3octA-2ogvA: 33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 VAL A 732 ALA A 749 LYS A 751 VAL A 781 THR A 796 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.79A	3octA-2r4bA: 29.0	3octA-2r4bA: 34.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 635 ALA A 651 LYS A 653 MET A 674 THR A 699 TYR A 701 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.9A) Q9G A1898 (-3.5A) Q9G A1898 (-4.8A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.75A	3octA-2xyuA: 14.0	3octA-2xyuA: 39.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 VAL A 261 ALA A 273 LYS A 275 MET A 294 THR A 319 GLY A 325 GLU A 335	None	1.19A	3octA-2zv7A: 32.2	3octA-2zv7A: 42.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	9	LEU A 253 VAL A 261 ALA A 273 LYS A 275 VAL A 303 THR A 319 GLY A 325 GLU A 335 LEU A 374	None	0.81A	3octA-2zv7A: 32.2	3octA-2zv7A: 42.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 487 VAL A 495 ALA A 515 LYS A 517 MET A 538 TYR A 566 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) None M33 A1996 ( 4.7A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.79A	3octA-3b2tA: 12.9	3octA-3b2tA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 209 ALA A 220 LYS A 222 MET A 240 VAL A 249 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.59A	3octA-3d7uA: 33.3	3octA-3d7uA: 43.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 VAL A 841 ALA A 859 LYS A 861 VAL A 892 TYR A 911 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.9A) None None	0.66A	3octA-3hngA: 29.6	3octA-3hngA: 32.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	8	VAL A 67 ALA A 80 LYS A 82 MET A 104 VAL A 113 TYR A 131 GLY A 135 LEU A 182	None	0.79A	3octA-3iecA: 23.0	3octA-3iecA: 25.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 696 VAL A 704 LYS A 723 VAL A 753 THR A 768 TYR A 770 GLY A 774 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 (-3.4A) None ANP A 1 ( 4.8A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A)	0.54A	3octA-3kexA: 27.2	3octA-3kexA: 28.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 665 LYS A 667 MET A 688 THR A 713 TYR A 715 GLY A 719 LEU A 767	None None None None GOL A 403 (-4.1A) GOL A 403 (-3.4A) None	0.66A	3octA-3kulA: 32.8	3octA-3kulA: 40.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	7	VAL A 218 ALA A 229 LYS A 231 THR A 279 TYR A 281 GLY A 285 LEU A 339	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None LDN A 1 (-3.8A) LDN A 1 ( 4.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A)	0.57A	3octA-3mdyA: 25.7	3octA-3mdyA: 26.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 49 VAL A 57 ALA A 70 LYS A 72 TYR A 122 GLY A 126 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None None XFE A 351 (-4.6A)	0.71A	3octA-3mvjA: 7.5	3octA-3mvjA: 24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 ALA A 227 LYS A 229 THR A 277 TYR A 279 GLY A 283 LEU A 337	LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-4.0A) LDN A 600 (-4.7A) LDN A 600 (-3.3A) LDN A 600 (-4.6A)	0.59A	3octA-3my0A: 25.4	3octA-3my0A: 27.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 88 VAL A 96 ALA A 109 LYS A 111 MET A 134 TYR A 161 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-2.8A) None None None None	0.67A	3octA-3nuuA: 8.5	3octA-3nuuA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 VAL A 200 ALA A 213 LYS A 215 VAL A 247 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None None AMP A 577 (-4.8A)	0.67A	3octA-3nyoA: 21.8	3octA-3nyoA: 18.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 726 VAL A 734 ALA A 751 LYS A 753 THR A 798 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.62A	3octA-3pp0A: 29.6	3octA-3pp0A: 32.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	9	VAL A 565 ALA A 576 LYS A 578 MET A 600 VAL A 609 THR A 625 TYR A 627 GLY A 631 LEU A 683	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-3.5A) None None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A)	0.55A	3octA-3ppzA: 29.6	3octA-3ppzA: 32.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 423 ALA A 443 LYS A 445 VAL A 473 THR A 489 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.64A	3octA-3sxsA: 34.6	3octA-3sxsA: 65.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 423 ALA A 443 LYS A 445 VAL A 473 THR A 489 TYR A 491 SER A 553	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 (-3.5A)	0.69A	3octA-3sxsA: 34.6	3octA-3sxsA: 65.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 423 VAL A 431 ALA A 443 MET A 464 VAL A 473 THR A 489 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.64A	3octA-3sxsA: 34.6	3octA-3sxsA: 65.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 423 VAL A 431 ALA A 443 MET A 464 VAL A 473 THR A 489 TYR A 491 SER A 553	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 (-3.5A)	0.75A	3octA-3sxsA: 34.6	3octA-3sxsA: 65.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 MET A 535 TYR A 563 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.5A) 07J A 1 (-3.8A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.78A	3octA-3tt0A: 29.8	3octA-3tt0A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 139 VAL A 147 ALA A 160 LYS A 162 TYR A 212 GLY A 216 LEU A 263	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 ( 4.1A) N13 A 501 (-2.9A) N13 A 501 (-4.4A) N13 A 501 (-3.5A) N13 A 501 (-4.5A)	0.69A	3octA-3w18A: 22.5	3octA-3w18A: 25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.65A	3octA-3wigA: 22.9	3octA-3wigA: 27.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 LYS A 868 VAL A 899 GLY A 922 LEU A1035	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None None LEV A1201 (-3.6A) LEV A1201 (-4.8A)	0.66A	3octA-3wzdA: 31.0	3octA-3wzdA: 34.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 ALA A 233 LYS A 235 THR A 283 TYR A 285 GLY A 289 LEU A 343	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) TAK A1507 (-3.6A) TAK A1507 ( 4.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A)	0.54A	3octA-4c02A: 25.4	3octA-4c02A: 27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 VAL A 254 ALA A 267 LYS A 269 TYR A 320 GLY A 324 LEU A 371	None	0.64A	3octA-4c0tA: 21.3	3octA-4c0tA: 13.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 663 VAL A 671 ALA A 684 LYS A 686 VAL A 721 TYR A 739 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) AGS A1985 (-3.0A) None None None AGS A1985 (-4.8A)	0.69A	3octA-4crsA: 8.6	3octA-4crsA: 26.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.56A	3octA-4f4pA: 29.5	3octA-4f4pA: 38.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 (-4.8A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.63A	3octA-4fl3A: 28.5	3octA-4fl3A: 18.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 828 VAL A 836 ALA A 853 LYS A 855 VAL A 884 TYR A 904 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-3.5A) None 19S A1201 (-4.7A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.63A	3octA-4hviA: 29.5	3octA-4hviA: 29.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.60A	3octA-4hzsA: 27.4	3octA-4hzsA: 32.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.61A	3octA-4id7A: 30.6	3octA-4id7A: 38.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 TYR A 340 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.60A	3octA-4k11A: 29.5	3octA-4k11A: 35.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 478 VAL A 486 ALA A 506 LYS A 508 MET A 529 TYR A 557 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 (-2.7A) None None ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.68A	3octA-4k33A: 31.7	3octA-4k33A: 35.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 33 VAL A 41 ALA A 54 LYS A 56 VAL A 83 TYR A 101 GLY A 105	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 403 ( 4.6A) GOL A 403 (-4.1A) GOL A 404 ( 4.9A) GOL A 404 (-3.6A)	0.57A	3octA-4lg4A: 8.7	3octA-4lg4A: 27.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 MET A 314 TYR A 340 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 3.6A) VGG A 601 ( 4.0A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.89A	3octA-4lggA: 29.2	3octA-4lggA: 38.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 TYR A 340 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) VGG A 601 ( 4.0A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.67A	3octA-4lggA: 29.2	3octA-4lggA: 38.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 46 VAL A 54 ALA A 67 LYS A 69 MET A 89 VAL A 99 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.71A	3octA-4o38A: 20.6	3octA-4o38A: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 LYS A 642 THR A 687 TYR A 689 GLY A 693 LEU A 741	2TT A1201 (-4.1A) 2TT A1201 (-4.2A) 2TT A1201 ( 4.6A) None 2TT A1201 (-4.0A) 2TT A1201 (-3.5A) 2TT A1201 (-4.1A)	0.71A	3octA-4oliA: 26.3	3octA-4oliA: 17.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 627 VAL A 635 ALA A 648 VAL A 685 TYR A 703 GLY A 707 LEU A 753	None	0.55A	3octA-4otdA: 22.0	3octA-4otdA: 26.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-3.4A) None P30 A1001 (-4.1A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.52A	3octA-4rt7A: 31.2	3octA-4rt7A: 32.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 LYS A 644 MET A 665 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 ( 3.7A) None P30 A1001 (-4.1A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.86A	3octA-4rt7A: 31.2	3octA-4rt7A: 32.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	LEU A 14 VAL A 22 ALA A 35 LYS A 37 MET A 56 THR A 81 TYR A 83 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.86A	3octA-4ueuA: 32.4	3octA-4ueuA: 50.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	LEU A 14 VAL A 22 ALA A 35 LYS A 37 VAL A 65 THR A 81 TYR A 83 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.52A	3octA-4ueuA: 32.4	3octA-4ueuA: 50.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	7	LEU A 104 VAL A 112 ALA A 125 LYS A 127 TYR A 177 GLY A 181 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) ATP A 501 (-2.6A) None None ATP A 501 (-4.5A)	0.68A	3octA-4wb7A: 7.6	3octA-4wb7A: 23.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	7	LEU A 104 VAL A 112 ALA A 125 LYS A 127 VAL A 159 TYR A 177 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) ATP A 501 (-2.6A) None None ATP A 501 (-4.5A)	0.73A	3octA-4wb7A: 7.6	3octA-4wb7A: 23.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 ALA A 214 LYS A 216 VAL A 248 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.73A	3octA-4wboA: 7.9	3octA-4wboA: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 MET A 94 VAL A 104 GLY A 132 LEU A 183	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-3.5A) KSA A 405 (-4.6A)	0.61A	3octA-4wsqA: 23.3	3octA-4wsqA: 25.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.51A	3octA-4xeyB: 13.6	3octA-4xeyB: 33.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 GLU B 348 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	1.11A	3octA-4xeyB: 13.6	3octA-4xeyB: 33.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.87A	3octA-4xi2A: 14.5	3octA-4xi2A: 97.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.0A) None P30 A1001 ( 4.4A) P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.71A	3octA-4xufA: 30.1	3octA-4xufA: 39.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	10	LEU A 408 VAL A 416 ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.7A) 746 A 702 (-4.4A) 746 A 702 (-3.6A) CA A 703 ( 4.5A) 746 A 702 (-4.4A)	0.97A	3octA-4y93A: 33.6	3octA-4y93A: 57.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 MET A 535 TYR A 563 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) EDO A1766 (-3.5A) 38O A1769 (-4.2A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.59A	3octA-5a46A: 30.0	3octA-5a46A: 30.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 ALA A 928 LYS A 930 TYR A 980 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None 5U3 A1200 (-4.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.48A	3octA-5f1zA: 28.2	3octA-5f1zA: 32.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 ALA A 756 LYS A 758 TYR A 806 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.61A	3octA-5fm2A: 31.4	3octA-5fm2A: 31.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 599 VAL A 607 ALA A 625 LYS A 627 MET A 648 VAL A 658 THR A 674 TYR A 676 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.4A) 748 A1001 ( 4.8A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.65A	3octA-5grnA: 13.0	3octA-5grnA: 33.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 94 ALA A 105 VAL A 134 THR A 148 TYR A 150 GLY A 154 LEU A 215	None	0.58A	3octA-5gz8A: 20.4	3octA-5gz8A: 24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	7	VAL A 93 ALA A 104 VAL A 133 THR A 147 TYR A 149 GLY A 153 LEU A 214	ADP A 401 (-4.4A) ADP A 401 (-3.2A) None ADP A 401 ( 4.8A) ADP A 401 ( 4.8A) ADP A 401 ( 4.1A) ADP A 401 (-4.4A)	0.57A	3octA-5gzaA: 19.5	3octA-5gzaA: 25.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 ALA A 77 LYS A 79 VAL A 109 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 ( 4.8A) None IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.71A	3octA-5i3oA: 23.6	3octA-5i3oA: 25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 ALA A 77 MET A 99 TYR A 132 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.63A	3octA-5i3oA: 23.6	3octA-5i3oA: 25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 ALA A 77 VAL A 109 TYR A 132 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.62A	3octA-5i3oA: 23.6	3octA-5i3oA: 25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 LYS A 45 MET A 65 VAL A 74 GLY A 96 LEU A 143	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) None None 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A)	0.71A	3octA-5j5tA: 22.3	3octA-5j5tA: 22.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 284 ALA A 297 LYS A 299 MET A 319 VAL A 328 TYR A 346 GLY A 350 LEU A 396	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 (-4.5A) IPW A 601 (-4.1A) None IPW A 601 (-4.5A) IPW A 601 ( 3.8A) IPW A 601 (-4.5A)	0.70A	3octA-5kbrA: 9.4	3octA-5kbrA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 106 ALA A 119 LYS A 121 VAL A 153 TYR A 171 GLY A 175 LEU A 221	None	0.63A	3octA-5u7qA: 3.2	3octA-5u7qA: 23.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	LEU A 24 ALA A 45 LYS A 47 THR A 95 TYR A 97 GLY A 101 GLU A 112 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) None 9WS A 401 (-4.6A)	0.84A	3octA-5w5jA: 24.3	3octA-5w5jA: 30.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	LEU A 24 VAL A 32 ALA A 45 THR A 95 TYR A 97 GLY A 101 GLU A 112 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) None 9WS A 401 (-4.6A)	0.75A	3octA-5w5jA: 24.3	3octA-5w5jA: 30.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	8	LEU A 891 VAL A 899 ALA A 917 LYS A 919 THR A 963 TYR A 965 GLY A 969 LEU A1017	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A)	0.67A	3octA-5wnoA: 27.9	3octA-5wnoA: 13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	7	VAL A 83 ALA A 95 LYS A 97 VAL A 125 TYR A 143 GLY A 147 LEU A 206	ANP A1000 (-4.1A) ANP A1000 (-3.2A) ANP A1000 (-2.8A) None ANP A1000 (-4.3A) None ANP A1000 (-4.5A)	0.61A	3octA-5xd6A: 6.7	3octA-5xd6A: 14.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	8	LEU A 33 VAL A 41 ALA A 54 LYS A 56 VAL A 83 TYR A 101 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None ANP A 501 ( 4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.70A	3octA-6ao5A: 22.8	3octA-6ao5A: 24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 LYS A 908 VAL A 938 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 (-2.8A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.54A	3octA-6c7yA: 9.8	3octA-6c7yA: 16.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	7	VAL A 200 ALA A 211 LYS A 213 VAL A 246 TYR A 264 GLY A 268 LEU A 318	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) CJT A 502 (-3.0A) None CJT A 502 (-4.5A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A)	0.69A	3octA-6f3dA: 23.8	3octA-6f3dA: 13.88

[["3OCT_A_1N1A663_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"LEU A 408;VAL A 416;LYS A 430;MET A 449;VAL A 458;GLY A 480;GLU A 488;LEU A 528","None","1.10A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;TYR A 476;GLY A 480;GLU A 488;LEU A 528","None","0.93A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",9,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528","None","0.86A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"VAL A 416;LYS A 430;MET A 449;VAL A 458;THR A 474;GLY A 480;GLU A 488;LEU A 528","None","1.08A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 209;ALA A 220;LYS A 222;MET A 240;VAL A 249;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.59A","3octA-1k9aA:32.3","3octA-1k9aA:27.97"],["3OCT_A_1N1A663_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",8,"VAL A 588;ALA A 606;LYS A 608;MET A 629;VAL A 638;TYR A 656;GLY A 660;LEU A 731","None","1.04A","3octA-1lufA:31.6","3octA-1lufA:30.72"],["3OCT_A_1N1A663_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;THR A 334;GLY A 340;GLU A 348;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","1.12A","3octA-1opkA:32.5","3octA-1opkA:28.69"],["3OCT_A_1N1A663_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.71A","3octA-1rjbA:29.8","3octA-1rjbA:36.36"],["3OCT_A_1N1A663_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;LYS A 644;MET A 665;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","1.00A","3octA-1rjbA:29.8","3octA-1rjbA:36.36"],["3OCT_A_1N1A663_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;VAL A 131;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.65A","3octA-1s9iA:22.3","3octA-1s9iA:24.15"],["3OCT_A_1N1A663_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;MET A 410;VAL A 419;GLY A 441;LEU A 489","None","0.68A","3octA-1snxA:14.9","3octA-1snxA:56.72"],["3OCT_A_1N1A663_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",9,"LEU A 595;VAL A 603;ALA A 621;LYS A 623;VAL A 654;THR A 670;TYR A 672;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-4.3A);STI A   3 (-3.2A);STI A   3 ( 4.0A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.70A","3octA-1t46A:30.2","3octA-1t46A:34.53"],["3OCT_A_1N1A663_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",7,"LEU A 344;VAL A 352;ALA A 367;MET A 390;VAL A 399;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);None;None;STU A 100 (-3.5A);STU A 100 (-4.5A)","0.67A","3octA-1u59A:29.9","3octA-1u59A:37.32"],["3OCT_A_1N1A663_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",8,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;VAL A  68;TYR A  86;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-4.8A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A)","0.59A","3octA-1zltA:22.4","3octA-1zltA:24.10"],["3OCT_A_1N1A663_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;ALA X  37;LYS X  39;MET X  58;VAL X  67;THR X  82;TYR X  84;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);None;None;STU X 902 (-4.1A);STU X 902 (-4.6A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.59A","3octA-2dq7X:31.8","3octA-2dq7X:38.38"],["3OCT_A_1N1A663_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;MET X  58;VAL X  67;THR X  82;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);None;None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.62A","3octA-2dq7X:31.8","3octA-2dq7X:38.38"],["3OCT_A_1N1A663_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;THR A 338;TYR A 340;GLY A 344;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;H8H A 534 (-3.1A);H8H A 534 (-4.3A);H8H A 534 (-3.3A);H8H A 534 (-4.5A)","0.52A","3octA-2h8hA:29.9","3octA-2h8hA:22.20"],["3OCT_A_1N1A663_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;THR A 338;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.74A","3octA-2hckA:29.8","3octA-2hckA:26.68"],["3OCT_A_1N1A663_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",10,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;MET A 292;VAL A 301;THR A 316;GLY A 322;GLU A 332;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);None;1BM A 499 (-4.4A)","1.07A","3octA-2hk5A:31.8","3octA-2hk5A:40.44"],["3OCT_A_1N1A663_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"LEU A 248;VAL A 256;ALA A 269;LYS A 271;MET A 290;VAL A 299;THR A 315;GLY A 321;GLU A 329;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);None;None;GIN A 600 (-4.7A)","1.25A","3octA-2hz0A:31.8","3octA-2hz0A:45.76"],["3OCT_A_1N1A663_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;ALA A 271;LYS A 273;MET A 292;THR A 316;TYR A 318;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.68A","3octA-2og8A:31.0","3octA-2og8A:42.48"],["3OCT_A_1N1A663_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;ALA A 271;LYS A 273;VAL A 301;THR A 316;TYR A 318;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.73A","3octA-2og8A:31.0","3octA-2og8A:42.48"],["3OCT_A_1N1A663_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;VAL A 301;THR A 316;TYR A 318","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A)","0.69A","3octA-2og8A:31.0","3octA-2og8A:42.48"],["3OCT_A_1N1A663_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;ALA A 614;LYS A 616;MET A 637;TYR A 665;GLY A 669;LEU A 785","None","0.61A","3octA-2ogvA:15.2","3octA-2ogvA:33.54"],["3OCT_A_1N1A663_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;ALA A 614;MET A 637;VAL A 647;THR A 663;TYR A 665;GLY A 669;LEU A 785","None","0.70A","3octA-2ogvA:15.2","3octA-2ogvA:33.54"],["3OCT_A_1N1A663_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;VAL A 596;ALA A 614;LYS A 616;MET A 637;GLY A 669;LEU A 785","None","0.68A","3octA-2ogvA:15.2","3octA-2ogvA:33.54"],["3OCT_A_1N1A663_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;MET A 637;VAL A 647;THR A 663;GLY A 669;LEU A 785","None","0.71A","3octA-2ogvA:15.2","3octA-2ogvA:33.54"],["3OCT_A_1N1A663_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;VAL A 732;ALA A 749;LYS A 751;VAL A 781;THR A 796;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.79A","3octA-2r4bA:29.0","3octA-2r4bA:34.71"],["3OCT_A_1N1A663_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",8,"VAL A 635;ALA A 651;LYS A 653;MET A 674;THR A 699;TYR A 701;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.9A);Q9G A1898 (-3.5A);Q9G A1898 (-4.8A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.75A","3octA-2xyuA:14.0","3octA-2xyuA:39.58"],["3OCT_A_1N1A663_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;VAL A 261;ALA A 273;LYS A 275;MET A 294;THR A 319;GLY A 325;GLU A 335","None","1.19A","3octA-2zv7A:32.2","3octA-2zv7A:42.28"],["3OCT_A_1N1A663_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",9,"LEU A 253;VAL A 261;ALA A 273;LYS A 275;VAL A 303;THR A 319;GLY A 325;GLU A 335;LEU A 374","None","0.81A","3octA-2zv7A:32.2","3octA-2zv7A:42.28"],["3OCT_A_1N1A663_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 487;VAL A 495;ALA A 515;LYS A 517;MET A 538;TYR A 566;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);None;M33 A1996 ( 4.7A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.79A","3octA-3b2tA:12.9","3octA-3b2tA:36.39"],["3OCT_A_1N1A663_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",9,"VAL A 209;ALA A 220;LYS A 222;MET A 240;VAL A 249;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.59A","3octA-3d7uA:33.3","3octA-3d7uA:43.45"],["3OCT_A_1N1A663_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;VAL A 841;ALA A 859;LYS A 861;VAL A 892;TYR A 911;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 ( 4.7A);8ST A2001 (-4.9A);None;None","0.66A","3octA-3hngA:29.6","3octA-3hngA:32.24"],["3OCT_A_1N1A663_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",8,"VAL A  67;ALA A  80;LYS A  82;MET A 104;VAL A 113;TYR A 131;GLY A 135;LEU A 182","None","0.79A","3octA-3iecA:23.0","3octA-3iecA:25.23"],["3OCT_A_1N1A663_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",8,"LEU A 696;VAL A 704;LYS A 723;VAL A 753;THR A 768;TYR A 770;GLY A 774;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 (-3.4A);None;ANP A   1 ( 4.8A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A)","0.54A","3octA-3kexA:27.2","3octA-3kexA:28.66"],["3OCT_A_1N1A663_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 665;LYS A 667;MET A 688;THR A 713;TYR A 715;GLY A 719;LEU A 767","None;None;None;None;GOL A 403 (-4.1A);GOL A 403 (-3.4A);None","0.66A","3octA-3kulA:32.8","3octA-3kulA:40.58"],["3OCT_A_1N1A663_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",7,"VAL A 218;ALA A 229;LYS A 231;THR A 279;TYR A 281;GLY A 285;LEU A 339","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;LDN A   1 (-3.8A);LDN A   1 ( 4.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A)","0.57A","3octA-3mdyA:25.7","3octA-3mdyA:26.69"],["3OCT_A_1N1A663_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",7,"LEU A  49;VAL A  57;ALA A  70;LYS A  72;TYR A 122;GLY A 126;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;None;XFE A 351 (-4.6A)","0.71A","3octA-3mvjA:7.5","3octA-3mvjA:24.16"],["3OCT_A_1N1A663_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;ALA A 227;LYS A 229;THR A 277;TYR A 279;GLY A 283;LEU A 337","LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-4.0A);LDN A 600 (-4.7A);LDN A 600 (-3.3A);LDN A 600 (-4.6A)","0.59A","3octA-3my0A:25.4","3octA-3my0A:27.73"],["3OCT_A_1N1A663_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",8,"LEU A  88;VAL A  96;ALA A 109;LYS A 111;MET A 134;TYR A 161;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-2.8A);None;None;None;None","0.67A","3octA-3nuuA:8.5","3octA-3nuuA:27.76"],["3OCT_A_1N1A663_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;VAL A 200;ALA A 213;LYS A 215;VAL A 247;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;None;AMP A 577 (-4.8A)","0.67A","3octA-3nyoA:21.8","3octA-3nyoA:18.40"],["3OCT_A_1N1A663_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"LEU A 726;VAL A 734;ALA A 751;LYS A 753;THR A 798;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.1A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.62A","3octA-3pp0A:29.6","3octA-3pp0A:32.29"],["3OCT_A_1N1A663_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",9,"VAL A 565;ALA A 576;LYS A 578;MET A 600;VAL A 609;THR A 625;TYR A 627;GLY A 631;LEU A 683","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-3.5A);None;None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A)","0.55A","3octA-3ppzA:29.6","3octA-3ppzA:32.16"],["3OCT_A_1N1A663_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",8,"LEU A 423;ALA A 443;LYS A 445;VAL A 473;THR A 489;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.64A","3octA-3sxsA:34.6","3octA-3sxsA:65.92"],["3OCT_A_1N1A663_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",7,"LEU A 423;ALA A 443;LYS A 445;VAL A 473;THR A 489;TYR A 491;SER A 553","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 (-3.5A)","0.69A","3octA-3sxsA:34.6","3octA-3sxsA:65.92"],["3OCT_A_1N1A663_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",9,"LEU A 423;VAL A 431;ALA A 443;MET A 464;VAL A 473;THR A 489;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.64A","3octA-3sxsA:34.6","3octA-3sxsA:65.92"],["3OCT_A_1N1A663_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",8,"LEU A 423;VAL A 431;ALA A 443;MET A 464;VAL A 473;THR A 489;TYR A 491;SER A 553","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 (-3.5A)","0.75A","3octA-3sxsA:34.6","3octA-3sxsA:65.92"],["3OCT_A_1N1A663_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;MET A 535;TYR A 563;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.5A);07J A   1 (-3.8A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.78A","3octA-3tt0A:29.8","3octA-3tt0A:28.53"],["3OCT_A_1N1A663_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",7,"LEU A 139;VAL A 147;ALA A 160;LYS A 162;TYR A 212;GLY A 216;LEU A 263","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 ( 4.1A);N13 A 501 (-2.9A);N13 A 501 (-4.4A);N13 A 501 (-3.5A);N13 A 501 (-4.5A)","0.69A","3octA-3w18A:22.5","3octA-3w18A:25.35"],["3OCT_A_1N1A663_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.65A","3octA-3wigA:22.9","3octA-3wigA:27.04"],["3OCT_A_1N1A663_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;LYS A 868;VAL A 899;GLY A 922;LEU A1035","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;None;LEV A1201 (-3.6A);LEV A1201 (-4.8A)","0.66A","3octA-3wzdA:31.0","3octA-3wzdA:34.42"],["3OCT_A_1N1A663_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;ALA A 233;LYS A 235;THR A 283;TYR A 285;GLY A 289;LEU A 343","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);TAK A1507 (-3.6A);TAK A1507 ( 4.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A)","0.54A","3octA-4c02A:25.4","3octA-4c02A:27.81"],["3OCT_A_1N1A663_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;VAL A 254;ALA A 267;LYS A 269;TYR A 320;GLY A 324;LEU A 371","None","0.64A","3octA-4c0tA:21.3","3octA-4c0tA:13.77"],["3OCT_A_1N1A663_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 663;VAL A 671;ALA A 684;LYS A 686;VAL A 721;TYR A 739;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);AGS A1985 (-3.0A);None;None;None;AGS A1985 (-4.8A)","0.69A","3octA-4crsA:8.6","3octA-4crsA:26.82"],["3OCT_A_1N1A663_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.56A","3octA-4f4pA:29.5","3octA-4f4pA:38.13"],["3OCT_A_1N1A663_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 (-4.8A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.63A","3octA-4fl3A:28.5","3octA-4fl3A:18.81"],["3OCT_A_1N1A663_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",8,"LEU A 828;VAL A 836;ALA A 853;LYS A 855;VAL A 884;TYR A 904;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-3.5A);None;19S A1201 (-4.7A);19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.63A","3octA-4hviA:29.5","3octA-4hviA:29.21"],["3OCT_A_1N1A663_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.60A","3octA-4hzsA:27.4","3octA-4hzsA:32.75"],["3OCT_A_1N1A663_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.61A","3octA-4id7A:30.6","3octA-4id7A:38.91"],["3OCT_A_1N1A663_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;TYR A 340;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.7A);0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.60A","3octA-4k11A:29.5","3octA-4k11A:35.78"],["3OCT_A_1N1A663_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"LEU A 478;VAL A 486;ALA A 506;LYS A 508;MET A 529;TYR A 557;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 (-2.7A);None;None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.68A","3octA-4k33A:31.7","3octA-4k33A:35.78"],["3OCT_A_1N1A663_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"LEU A  33;VAL A  41;ALA A  54;LYS A  56;VAL A  83;TYR A 101;GLY A 105","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 403 ( 4.6A);GOL A 403 (-4.1A);GOL A 404 ( 4.9A);GOL A 404 (-3.6A)","0.57A","3octA-4lg4A:8.7","3octA-4lg4A:27.34"],["3OCT_A_1N1A663_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;MET A 314;TYR A 340;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 3.6A);VGG A 601 ( 4.0A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.89A","3octA-4lggA:29.2","3octA-4lggA:38.85"],["3OCT_A_1N1A663_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;TYR A 340;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);VGG A 601 ( 4.0A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.67A","3octA-4lggA:29.2","3octA-4lggA:38.85"],["3OCT_A_1N1A663_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",9,"LEU A  46;VAL A  54;ALA A  67;LYS A  69;MET A  89;VAL A  99;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.71A","3octA-4o38A:20.6","3octA-4o38A:25.75"],["3OCT_A_1N1A663_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;LYS A 642;THR A 687;TYR A 689;GLY A 693;LEU A 741","2TT A1201 (-4.1A);2TT A1201 (-4.2A);2TT A1201 ( 4.6A);None;2TT A1201 (-4.0A);2TT A1201 (-3.5A);2TT A1201 (-4.1A)","0.71A","3octA-4oliA:26.3","3octA-4oliA:17.67"],["3OCT_A_1N1A663_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 627;VAL A 635;ALA A 648;VAL A 685;TYR A 703;GLY A 707;LEU A 753","None","0.55A","3octA-4otdA:22.0","3octA-4otdA:26.32"],["3OCT_A_1N1A663_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-3.4A);None;P30 A1001 (-4.1A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.52A","3octA-4rt7A:31.2","3octA-4rt7A:32.00"],["3OCT_A_1N1A663_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;LYS A 644;MET A 665;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 ( 3.7A);None;P30 A1001 (-4.1A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.86A","3octA-4rt7A:31.2","3octA-4rt7A:32.00"],["3OCT_A_1N1A663_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"LEU A  14;VAL A  22;ALA A  35;LYS A  37;MET A  56;THR A  81;TYR A  83;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.86A","3octA-4ueuA:32.4","3octA-4ueuA:50.19"],["3OCT_A_1N1A663_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"LEU A  14;VAL A  22;ALA A  35;LYS A  37;VAL A  65;THR A  81;TYR A  83;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.52A","3octA-4ueuA:32.4","3octA-4ueuA:50.19"],["3OCT_A_1N1A663_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",7,"LEU A 104;VAL A 112;ALA A 125;LYS A 127;TYR A 177;GLY A 181;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);ATP A 501 (-2.6A);None;None;ATP A 501 (-4.5A)","0.68A","3octA-4wb7A:7.6","3octA-4wb7A:23.63"],["3OCT_A_1N1A663_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",7,"LEU A 104;VAL A 112;ALA A 125;LYS A 127;VAL A 159;TYR A 177;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);ATP A 501 (-2.6A);None;None;ATP A 501 (-4.5A)","0.73A","3octA-4wb7A:7.6","3octA-4wb7A:23.63"],["3OCT_A_1N1A663_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;ALA A 214;LYS A 216;VAL A 248;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.73A","3octA-4wboA:7.9","3octA-4wboA:20.00"],["3OCT_A_1N1A663_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;MET A  94;VAL A 104;GLY A 132;LEU A 183","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-3.5A);KSA A 405 (-4.6A)","0.61A","3octA-4wsqA:23.3","3octA-4wsqA:25.39"],["3OCT_A_1N1A663_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.51A","3octA-4xeyB:13.6","3octA-4xeyB:33.76"],["3OCT_A_1N1A663_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;GLU B 348;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","1.11A","3octA-4xeyB:13.6","3octA-4xeyB:33.76"],["3OCT_A_1N1A663_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.87A","3octA-4xi2A:14.5","3octA-4xi2A:97.39"],["3OCT_A_1N1A663_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.0A);None;P30 A1001 ( 4.4A);P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.71A","3octA-4xufA:30.1","3octA-4xufA:39.93"],["3OCT_A_1N1A663_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",10,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.7A);746 A 702 (-4.4A);746 A 702 (-3.6A); CA A 703 ( 4.5A);746 A 702 (-4.4A)","0.97A","3octA-4y93A:33.6","3octA-4y93A:57.66"],["3OCT_A_1N1A663_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;MET A 535;TYR A 563;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);EDO A1766 (-3.5A);38O A1769 (-4.2A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.59A","3octA-5a46A:30.0","3octA-5a46A:30.08"],["3OCT_A_1N1A663_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;ALA A 928;LYS A 930;TYR A 980;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;5U3 A1200 (-4.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.48A","3octA-5f1zA:28.2","3octA-5f1zA:32.88"],["3OCT_A_1N1A663_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;ALA A 756;LYS A 758;TYR A 806;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.61A","3octA-5fm2A:31.4","3octA-5fm2A:31.65"],["3OCT_A_1N1A663_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",10,"LEU A 599;VAL A 607;ALA A 625;LYS A 627;MET A 648;VAL A 658;THR A 674;TYR A 676;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.4A);748 A1001 ( 4.8A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.65A","3octA-5grnA:13.0","3octA-5grnA:33.61"],["3OCT_A_1N1A663_1","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  94;ALA A 105;VAL A 134;THR A 148;TYR A 150;GLY A 154;LEU A 215","None","0.58A","3octA-5gz8A:20.4","3octA-5gz8A:24.15"],["3OCT_A_1N1A663_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  93;ALA A 104;VAL A 133;THR A 147;TYR A 149;GLY A 153;LEU A 214","ADP A 401 (-4.4A);ADP A 401 (-3.2A);None;ADP A 401 ( 4.8A);ADP A 401 ( 4.8A);ADP A 401 ( 4.1A);ADP A 401 (-4.4A)","0.57A","3octA-5gzaA:19.5","3octA-5gzaA:25.81"],["3OCT_A_1N1A663_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;ALA A  77;LYS A  79;VAL A 109;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 ( 4.8A);None;IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.71A","3octA-5i3oA:23.6","3octA-5i3oA:25.32"],["3OCT_A_1N1A663_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;ALA A  77;MET A  99;TYR A 132;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.63A","3octA-5i3oA:23.6","3octA-5i3oA:25.32"],["3OCT_A_1N1A663_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;ALA A  77;VAL A 109;TYR A 132;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.62A","3octA-5i3oA:23.6","3octA-5i3oA:25.32"],["3OCT_A_1N1A663_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;LYS A  45;MET A  65;VAL A  74;GLY A  96;LEU A 143","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);None;None;6G2 A 901 (-3.6A);6G2 A 901 (-4.7A)","0.71A","3octA-5j5tA:22.3","3octA-5j5tA:22.14"],["3OCT_A_1N1A663_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",8,"VAL A 284;ALA A 297;LYS A 299;MET A 319;VAL A 328;TYR A 346;GLY A 350;LEU A 396","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 (-4.5A);IPW A 601 (-4.1A);None;IPW A 601 (-4.5A);IPW A 601 ( 3.8A);IPW A 601 (-4.5A)","0.70A","3octA-5kbrA:9.4","3octA-5kbrA:26.30"],["3OCT_A_1N1A663_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A 106;ALA A 119;LYS A 121;VAL A 153;TYR A 171;GLY A 175;LEU A 221","None","0.63A","3octA-5u7qA:3.2","3octA-5u7qA:23.46"],["3OCT_A_1N1A663_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"LEU A  24;ALA A  45;LYS A  47;THR A  95;TYR A  97;GLY A 101;GLU A 112;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);None;9WS A 401 (-4.6A)","0.84A","3octA-5w5jA:24.3","3octA-5w5jA:30.19"],["3OCT_A_1N1A663_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"LEU A  24;VAL A  32;ALA A  45;THR A  95;TYR A  97;GLY A 101;GLU A 112;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);None;9WS A 401 (-4.6A)","0.75A","3octA-5w5jA:24.3","3octA-5w5jA:30.19"],["3OCT_A_1N1A663_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",8,"LEU A 891;VAL A 899;ALA A 917;LYS A 919;THR A 963;TYR A 965;GLY A 969;LEU A1017","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A)","0.67A","3octA-5wnoA:27.9","3octA-5wnoA:13.62"],["3OCT_A_1N1A663_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",7,"VAL A  83;ALA A  95;LYS A  97;VAL A 125;TYR A 143;GLY A 147;LEU A 206","ANP A1000 (-4.1A);ANP A1000 (-3.2A);ANP A1000 (-2.8A);None;ANP A1000 (-4.3A);None;ANP A1000 (-4.5A)","0.61A","3octA-5xd6A:6.7","3octA-5xd6A:14.18"],["3OCT_A_1N1A663_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",8,"LEU A  33;VAL A  41;ALA A  54;LYS A  56;VAL A  83;TYR A 101;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.70A","3octA-6ao5A:22.8","3octA-6ao5A:24.59"],["3OCT_A_1N1A663_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;LYS A 908;VAL A 938;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.54A","3octA-6c7yA:9.8","3octA-6c7yA:16.04"],["3OCT_A_1N1A663_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",7,"VAL A 200;ALA A 211;LYS A 213;VAL A 246;TYR A 264;GLY A 268;LEU A 318","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);CJT A 502 (-3.0A);None;CJT A 502 (-4.5A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A)","0.69A","3octA-6f3dA:23.8","3octA-6f3dA:13.88"]]